1 |
50 PLIVA and Microsoft sign global purchasing agreement</a></b><br> |
2 |
<i>Zagreb, 18 January 2001.</i><br> |
3 |
PLIVA and Microsoft signed the Microsoft Enterprise |
4 |
Agreement - an agreement lasting several years which enables PLIVA to standardise |
5 |
Microsoft technology on its computers in facilities in Croatia and throughout Central |
6 |
and Eastern Europe. |
7 |
|
8 |
49 PLIVA acquires Dominion</a></b><br> |
9 |
<i>Zagreb, 19 December 2000.</i><br> |
10 |
PLIVA d.d. ("PLIVA") announced today that is has acquired Pharmascience UK |
11 |
Limited, 100% owner of Dominion Pharma Limited ("Dominion"), for |
12 |
a total cash consideration of GBP 3.4 million. |
13 |
|
14 |
48 PLIVA and Zagrebacka banka Agreement</a></b><br> |
15 |
<i>Zagreb, 19 December 2000.</i><br> |
16 |
PLIVA d.d. (PLIVA) and Zagrebacka banka (ZABA) today announced that they have |
17 |
reached an agreement regarding the sale of ZABA's 2.5% equity stake in PLIVA. |
18 |
|
19 |
47 VETERINA d.o.o. Established</a></b><br> |
20 |
<i>Zagreb, 8 December 2000.</i><br> |
21 |
Based on strategic orientation to pharmaceuticals as its core business, PLIVA has |
22 |
decided to spin off its Animal Health & Agrochemicals business segment into an |
23 |
independent company in its full ownership. |
24 |
|
25 |
46 Engineer from PLIVA wins golden award for innovation</a></b><br> |
26 |
<i>Zagreb, 8 December 2000.</i><br> |
27 |
PLIVA's employee Srecko Brkic, a mechanical engineer in Technical Operations, won |
28 |
the golden award at the 49th World Fair of Innovation, Research and New Technologies |
29 |
EUREKA 2000 |
30 |
|
31 |
45 Simplified customs procedures for the company</a></b><br> |
32 |
<i>Zagreb, 8 December 2000.</i><br> |
33 |
Today PLIVA started implementing simplified customs procedures, granted to the company |
34 |
as part of a pilot-project by the Customs Administration of the Republic of Croatia. |
35 |
|
36 |
44 PLIVA s R&D Day in London on November 29, 2000 Balanced Portfolio for Short, Medium and Long Term Growth</a></b><br> |
37 |
<i>Zagreb, 29 November 2000.</i> |
38 |
|
39 |
43 PLIVA signs USD 85 m Credit Facility Agreement with EBRD and IFC</a></b><br> |
40 |
<i>Zagreb, 20 November 2000.</i><br> |
41 |
PLIVA d.d.(PLIVA) today announced that it signed a credit facility agreement |
42 |
(The Agreement) with the European Bank for Reconstruction and Development (EBRD) |
43 |
and the International Finance Corporation (IFC) on 17 November 2000. |
44 |
|
45 |
42 PLIVA's subsidiary NEVA d.o.o. obtains the ISO 14001 environmental management system certification</a></b><br> |
46 |
<i>Zagreb, 15 November 2000.</i><br> |
47 |
In the presence of Mr. Roland Zuvanic, Deputy Minister of Environmental Protection |
48 |
and Zoning, and Mr. Zeljko Covic, President of the Management Board and CEO of PLIVA, |
49 |
Mr. Leonardo Omodeo-Zorini, representative of the Norwegian certification company DNV |
50 |
presented the certificate to NEVA's director Ms. Sanja Slunjski. |
51 |
|
52 |
41 Encouragement to young scientists</a></b><br> |
53 |
<i>Zagreb, 14 November 2000.</i><br> |
54 |
On 14 November 2000 PLIVA and the Croatian Chemical Society presented |
55 |
the Organic Chemistry Award Vladimir Prelog for the fourth time. This year |
56 |
the award was presented to Valerije Vrcek, Ph.D., a young scientist from |
57 |
the Faculty of Pharmacy and Biochemistry in Zagreb. |
58 |
|
59 |
40 State and business delegation from Turkey visits PLIVA</a></b><br> |
60 |
<i>Zagreb, 28 September 2000.</i><br> |
61 |
A state and business delegation from Turkey was in an official visit to Zagreb from 26 to 28 |
62 |
September 2000. The delegation was led by Minister of Health of the Republic of Turkey, Mr. Osman Durmus. |
63 |
|
64 |
39 PLIVA divests Lachema's non-core operations in Blansko</a></b><br> |
65 |
<i>Zagreb, 11 September 2000.</i><br> |
66 |
PLIVA d.d. ('PLIVA') announced today that it has signed an agreement with Synthon s.r.o., |
67 |
subsidiary of the Dutch firm Synthon BV, regarding the sale of Lachema's |
68 |
non-core operations in Blansko, Czech Republic. |
69 |
|
70 |
|
71 |
38 A New Mandate for the Members of PLIVA's MB</a></b><br> |
72 |
<i>Zagreb, 7 September 2000.</i><br> |
73 |
As the mandates of PLIVA's Management Board members are expiring, the company's |
74 |
Supervisory Board appointed the Management Board members for a new five-year period. |
75 |
|
76 |
37 PLIVA's Scientists - Heroes of Chemistry</a></b><br> |
77 |
<i>Zagreb, 20 August 2000.</i><br> |
78 |
The "Heroes of Chemistry |
79 |
2000"ceremony was held on 20 August 2000 in Washington D.C., USA, organised |
80 |
by the American Chemical Society (ACS), a non-profit association of American |
81 |
chemists and chemical engineers and the largest association of scientists in the |
82 |
world. |
83 |
|
84 |
36 Special Announcement</a></b><br> |
85 |
<i>Zagreb, 18 July 2000.</i><br> |
86 |
We would like to inform you that |
87 |
PLIVA's annual summer holiday will last from July 24th to August 14th. |
88 |
|
89 |
35 PLIVA to reduce workforce by the end of 2000</a></b><br> |
90 |
<i>Zagreb, 3 July 2000.</i><br> |
91 |
PLIVA d.d. ('PLIVA') announced today that it will significantly reduce its total |
92 |
workforce by the end of the year. |
93 |
|
94 |
34 PLIVA's Annual General Meeting</a></b><br> |
95 |
<i>Zagreb, 8 June 2000.</i><br> |
96 |
The General Assembly of PLIVA d.d. shareholders was held today. The PLIVA Management Board presented Company's 1999 |
97 |
operations and position, while the Supervisory Board gave a presentation on |
98 |
their monitoring of the Company's management of affairs. |
99 |
|
100 |
33 PLIVA Granted License for an Anti-Fungal NCE by BAYER AG</a></b><br> |
101 |
<i>Zagreb, 23 May 2000.</i><br> |
102 |
PLIVA d.d. ('PLIVA') announced today that it has received a license |
103 |
for a new chemical entity for the treatment of fungal infections from |
104 |
BAYER AG, Germany, a compound in its final stage of pre-clinical |
105 |
trials. |
106 |
|
107 |
32 Chinese Minister of Health Visits PLIVA</a></b><br> |
108 |
<i>Zagreb, 20 May 2000.</i><br> |
109 |
A high-level delegation headed by Mr. Zhang Wenkang, Minister of Health of |
110 |
The People's Republic of China, is visiting Croatia. The Mr. Wenkang's |
111 |
visit has been organised by the Croatian Ministry of Health and the |
112 |
Chinese Embassy. |
113 |
|
114 |
31 Additional Stake Acquired in Lachema</a></b><br> |
115 |
<i>Zagreb, 27 April 2000.</i><br> |
116 |
PLIVA announced today that it has |
117 |
signed an agreement with an institutional investor for the purchase of 26.08% of |
118 |
the total share capital of Lachema, the Czech pharmaceutical company, for cash |
119 |
consideration of USD 4,945,308.49. |
120 |
|
121 |
30 PLIVA Group 1999 Full Year Results</a><br> |
122 |
<i>Zagreb, 23 March 2000.<br> |
123 |
With a 26.2% growth in net |
124 |
income to HRK 869.1 m, PLIVA achieved strong operating results in 1999, |
125 |
despite unfavourable conditions in the surrounding region. |
126 |
|
127 |
29 PLIVA sells 75% stake in its Yeast Subsidiary<br> |
128 |
</b><i>Zagreb, March 1, 2000.</i><br> |
129 |
PLIVA d.d. ('PLIVA') announced that it has signed an |
130 |
agreement to sell its yeast operations carried out through its Croatian |
131 |
subsidiary SAF Kvasac d.o.o. to Cie des Levures Lesaffre, todays world leader |
132 |
in the production of yeast and yeast extracts. |
133 |
|
134 |
28 New drug forms and prices</a><br> |
135 |
</b><i>Zagreb, 15 February 2000.</i><br> |
136 |
The Croatian Institute |
137 |
for Health Insurance has announced its reimbursment list as of 15 February 2000. |
138 |
This includes five new drug forms produced by PLIVA |
139 |
|
140 |
27 PLIVA ups stake in PLIVA Krakow</a><br> |
141 |
</b><i>Zagreb, December 16, 1999.</i><br> |
142 |
PLIVA today announced that it has acquired |
143 |
an additional 6.17 per cent share capital of PLIVA Krakow S.A. from |
144 |
Handlowy Investments S.A., for a cash consideration of USD 16,008,726.29. |
145 |
|
146 |
26 Management Board Changes</a><br> |
147 |
</b><i>Zagreb, December 9, 1999.</i><br> |
148 |
The organisational changes resulting from the PLIVA XXI project and the |
149 |
further internationalisation of the Companys activities entail changes |
150 |
in the roles and responsibilities of the members of the Management Board. |
151 |
|
152 |
25 Y2k Preparations</a><br> |
153 |
<i>Zagreb, 6 December 1999.<br> |
154 |
We at PLIVA |
155 |
d.d. are fully aware of the need for Y2k compliance to avoid any business |
156 |
disruption associated with computer software, hardware and embedded |
157 |
systems that are incapable of managing dates beyond the year 1999. |
158 |
|
159 |
24 Lachema Acquisition Finalised</a><br> |
160 |
</b><i>Zagreb, December 3, 1999.</i><br> |
161 |
PLIVA today announced that the acquisition of 66,67% stake of the Czech pharmaceutical |
162 |
company, Lachema, was completed yesterday when PLIVA Krakow, PLIVAs |
163 |
subsidiary paid agreed price of USD 26.5 million. |
164 |
|
165 |
23 PLIVA Acquires Czech Lachema</a><br> |
166 |
<i>Zagreb, 12 November 1999.<br> |
167 |
</i>PLIVA |
168 |
has announced that it has signed agreements for the purchase of a 66.67% |
169 |
stake in Lachema, the Czech pharmaceutical company, for a cash |
170 |
consideration of USD 26.5 million from the companys institutional |
171 |
investors. |
172 |
|
173 |
22 Notice to PLIVA d.d. Shareholders</a><br> |
174 |
<i>Zagreb, 26 October 1999.<br> |
175 |
</i>According |
176 |
to the decision of the General Assembly of PLIVA d.d. shareholders held on 03 |
177 |
June 1999 concerning distribution of dividends to shareholders, PLIVA d.d. |
178 |
should pay the 1998 dividend not later than 31 December 1999. |
179 |
|
180 |
21 Predrag Novak Receives Phys. Chem. Award</a><br> |
181 |
<i>Zagreb, 26 October 1999.<br> |
182 |
The |
183 |
award presented each year by the Croatian Chemical Society for |
184 |
achievements in the field of physical chemistry was presented to Predrag |
185 |
Novak, Ph.D., who works in PLIVAs Research Institute, at a ceremony |
186 |
held at the Rudjer Boskovic Institute on Tuesday, October 19th. |
187 |
|
188 |
|
189 |
20 PLIVA Facilities Pass FDA Inspection</a><br> |
190 |
</b><i>Zagreb, 27 October 1999.</i><br> |
191 |
PLIVAs new Azithromycin facility was found to be in compliance with good |
192 |
manufacturing practice according to the Food and Drug Administration (FDA) inspection carried out |
193 |
in mid-October of 1999. |
194 |
|
195 |
|
196 |
19 Virlix® Price Approval Application at PLIVA-Krakow.</a><br> |
197 |
<i>Zagreb, 14 October 1999.<br> |
198 |
PLIVA Krakow has applied for price approval of the drug Virlix® |
199 |
10mg*20tab. (cetirizine) which will replace the product Zyrtec® |
200 |
10mg*20tab. (cetirizine) in PLIVA Krakows product portfolio. |
201 |
|
202 |
18 Successful Debt Collection and the VAT</a><br> |
203 |
</b><i>Zagreb, 14 October 1999.</i><br> |
204 |
As |
205 |
a result of a restrictive sales policy and higher collection from the |
206 |
healthcare sector, in the last three months, PLIVA has recorded a decrease |
207 |
in receivables from the Croatian healthcare sector, from HRK 613 million |
208 |
at the end of June 1999 to HRK 400 million to date. |
209 |
|
210 |
17 Vladimir Prelog Organic Chemistry Award.</a><br> |
211 |
</b><i>Zagreb, 14 October 1999.</i><br> |
212 |
The Vladimir Prelog Organic Chemistry Award was established in 1996 as a |
213 |
means to encourage young Croatian scientists in the field of organic |
214 |
chemistry. Its founders were PLIVA d.d. and the Croatian Chemical Society. |
215 |
|
216 |
16 PLIVA CEO, Zeljko Covic, named 1999 Emerging Markets CEO of the Year</a><br> |
217 |
</b><i>Zagreb, 28 September 1999.<br> |
218 |
The selection Committee for the 1999 Emerging Markets CEO of the Year |
219 |
Awards has selected Zeljko Covic, President of PLIVA's Management |
220 |
Board, and PLIVA, as the Europe, Middle East and Africa Award |
221 |
winner. |
222 |
15 PLIVA GROUP RESULTS FOR 1H 1999.</a><br> |
223 |
<i>Zagreb, 16 September, 1999.</i><br> |
224 |
Despite challenges in the operating environment (Kosovo crisis, |
225 |
the introduction of<span style="mso-spacerun: yes"> </span>a |
226 |
reference price system and illiquidity in the Croatian health-care |
227 |
sector, introduction of a new health-care system in Poland and the |
228 |
continuation of the Russian crisis), PLIVA achieved good results in |
229 |
the first six months. |
230 |
14 Organisational Changes</a></b><br> |
231 |
<i>Zagreb, 1st July 1999.</i><br> |
232 |
In response to changes in the environment, and with the aim |
233 |
of generating long-term growth, PLIVA has defined a new strategy |
234 |
within the activities of its PLIVA XXI project. The strategy is |
235 |
based on pharmaceuticals being the core-business, continuously |
236 |
increasing R&D investments and intensifying the |
237 |
internationalisation of the company. |
238 |
13 Continued Strong Growth of Zithromax (Azithromycin) Sales</a><br> |
239 |
</b><i>Zagreb, 20th April 1999.</i><b><br> |
240 |
</b>"Global sales of Zithromax (azithromycin), a broad-spectrum |
241 |
oral antibiotic increased by 44 percent to US$ 441 million in the |
242 |
first quarter of 1999", Pfizer reported last week. "Growth |
243 |
in sales resulted form physicians' increasing recognition of the |
244 |
product's broad efficacy, compliance advantages, favourable |
245 |
side-effect profile and, in liquid formulation for children, a |
246 |
pleasant taste. Zithromax continues to be the most prescribed |
247 |
brand-name prescription antibiotic in the U.S," added Pfizer in |
248 |
its Press Release. |
249 |
12 PLIVA announces acquisition of MIXIS GENETICS Ltd.</a><br> |
250 |
</b><i>Zagreb, 15th April 1999.</i><b><br> |
251 |
</b>PLIVA, the largest pharmaceuticals company in Central and |
252 |
Eastern Europe announces that it has acquired 100% ownership of the |
253 |
company MIXIS GENETICS Ltd. ("MIXIS") for US$ 3.3 million. |
254 |
By this transaction PLIVA becomes the owner of several patents |
255 |
covering break-through technologies in the field of biodiversity. |
256 |
11 PLIVA GROUP 1998 FULL YEAR RESULTS</a><br> |
257 |
</b><i>Zagreb, 12th April 1999.</i><b><br> |
258 |
</b>PLIVA, the largest pharmaceuticals company in Central and |
259 |
Eastern Europe and listed on the London and Zagreb Stock Exchanges, |
260 |
today announces excellent full year results for the financial year |
261 |
1998. |
262 |
10 PLIVA AND THE ALTHEXIS COMPANY ANNOUNCE A COLLABORATION ON THE STRUCTURE-BASED DRUG DESIGN OF NOVEL BROAD SPECTRUM ANTIBIOTICS</a><br> |
263 |
</b><i>Zagreb, 8th February 1999.</i><b><br> |
264 |
</b>PLIVA d.d., Zagreb, Croatia and The Althexis Company, Inc., |
265 |
Boston, MA., USA, today announced that they have entered into a |
266 |
collaboration to develop and commercialise novel broad spectrum |
267 |
antibiotics using structure-based drug design ("SBDD") |
268 |
technologies. PLIVA support for the Althexis program may total $14.4 |
269 |
million over three years in research funding and milestone payments. |
270 |
Additional future revenues to Althexis and PLIVA may result from |
271 |
certain exclusive marketing rights each retains under the |
272 |
collaboration agreement. |
273 |
9 PLIVA d.d. ANNOUNCES JOINT RESEARCH VENTURE WITH GLAXO WELLCOME PLC TO FIND NEW ANTIBIOTICS TO BEAT TREATMENT RESISTANCE</a><br> |
274 |
</b><i>Zagreb, 1st February 1999.</i><b><br> |
275 |
</b>PLIVA, the largest pharmaceutical company from Central and |
276 |
Eastern Europe, announces that they are today signing a Memorandum |
277 |
of Understanding with the UK-based pharmaceutical company, Glaxo |
278 |
Wellcome plc, for a research collaboration aimed at finding the next |
279 |
generation of macrolide antibiotics, capable of overcoming the |
280 |
growing problem of treatment resistance. |
281 |
8 INTRODUCING A REFERENCE PRICE SYSTEM FOR PHARMACEUTICAL PRODUCTS IN CROATIA AND ITS INFLUENCE ON PLIVA'S BUSINESS PERFORMANCE</a><br> |
282 |
</b><i>Zagreb, 20 January 1999.</i><b><br> |
283 |
</b>Prompted by the Ministry of Health, the Croatian Institute for |
284 |
Health Insurance ("HZZO") has announced its intention to |
285 |
introduce, as of 01 February 1999, a system of so-called reference |
286 |
prices for all pharmaceutical products reimbursed by state health |
287 |
insurance. Accordingly, PLIVA d.d. ("PLIVA"), the largest |
288 |
pharmaceutical company in Croatia and leading pharmaceutical group |
289 |
in Central and Eastern Europe, has commenced negotiations with the |
290 |
Ministry of Health and HZZO about determining new prices of drugs. |
291 |
7 PLIVA LAUNCHES NEW STRATEGY FOR THE 21st CENTURY</a><br> |
292 |
</b><i>Zagreb, 17 December 1998.</i><b><br> |
293 |
</b>PLIVAs new vision and new strategy represents the companys |
294 |
response to the challenges that globalisation is setting before |
295 |
pharmaceutical companies. At the same time, it represents an |
296 |
adjustment to the times and circumstances which characterise this |
297 |
industry at the end of the 90s and will depict the trends in the |
298 |
next decade. |
299 |
|
300 |
6 PLIVA TO BUY POLISH PHARMACEUTICAL COMPANY FARMACOM</a><br> |
301 |
</strong><i>Zagreb, 14 December 1998.</i><strong><br> |
302 |
The Memorandum of Understanding deals with PLIVA's |
303 |
intention to purchase a 60% stake in the Polish pharmaceutical |
304 |
company FARMACOM whose head office is situated in Krakow, Poland. |
305 |
5 <strong>POLFA KRAKOW CHANGES NAME TO PLIVA KRAKOW</strong></a><br> |
306 |
<i>Zagreb, 14 December 1998.</i><br> |
307 |
POLFA Krakows General Assembly decided to change the name of the |
308 |
company at its meeting held on 30 November 1998. The new name - |
309 |
PLIVA Krakow - will be officially used after completion of legal |
310 |
procedures dealing with the registration which will be carried out |
311 |
at the Polish court with jurisdiction over the matter. |
312 |
|
313 |
4 <strong>PLIVA AND PRIVREDNA BANKA ZAGREB SIGN COMMERCIAL PAPER CONTRACT</strong></a><br> |
314 |
<i> |
315 |
Zagreb, 11th December 1998.</i> |
316 |
On 11 December 1998, |
317 |
PLIVA, the leading pharmaceutical company from Central and Eastern |
318 |
Europe, signed a contract with Privredna banka Zagreb for issuing |
319 |
and selling PLIVAs commercial papers on the Croatian money |
320 |
market. The contract defines a HRK 400 million commercial paper |
321 |
programme. |
322 |
|
323 |
3 <strong>PLIVA SIGNS A USD 100 MILLION WORTH EURO-COMMERCIAL PAPER PROGRAM</strong></a><br> |
324 |
Zagreb, 4th December 1998</i><i>.</i> |
325 |
<br> |
326 |
PLIVA, the largest |
327 |
pharmaceutical company from Central and Eastern Europe signs a USD |
328 |
100 million worth Euro-commercial paper program and gain |
329 |
access to the debt marketIn Vienna on Friday 4 December, PLIVA |
330 |
signed a contract with six European banks which allows it to issue |
331 |
Euro commercial papers up to USD 100 million on the Euro market. |
332 |
2 RESPONSE TO SPECULATION RELATING TO LEK |
333 |
Zagreb, 5th October 1998 |
334 |
PLIVA, the largest |
335 |
pharmaceutical company from CEE, today denied the press speculation |
336 |
that it may be intending to make a hostile takeover bid for Lek, the |
337 |
Slovenian pharmaceutical company based in Ljubljana. |
338 |
1 PLIVA ACQUIRES WORLD-WIDE RIGHTS FOR A NEW COMPOUND WITH THROMBOPOIETIN-LIKE ACTIVITY |
339 |
Zagreb, 7th September 1998.</small></i> |
340 |
The action of the |
341 |
compound is distinctly different from thrombopoietin and constitutes |
342 |
a strong alternative or complement to thrombopoietin . |
343 |
|
344 |
0 1998 HALF YEAR RESULTS - CONTINUED STRONG PERFORMANCE<br> |
345 |
Zagreb, 4th September 1998. |
346 |
OPERATING PROFIT UP BY 28.6% PLIVA, the largest pharmaceutical company in Central & |
347 |
Eastern Europe, listed on the London and Zagreb Stock Exchanges, |
348 |
today announced excellent results for the first half of 1998. |
349 |
-1 PLIVA OPENS NEW STATE-OF-THE-ART AZITHROMYCIN PRODUCTION FACILITY</b><br> |
350 |
</a><i>Zagreb, 4th September 1998</i><i>.</i><br> |
351 |
PLIVA, the largest pharmaceutical company in Central |
352 |
and Eastern Europe, announces that its new Azithromycin production |
353 |
plant has been completed. The project worth US$ 100 million is |
354 |
PLIVAs biggest investment in a production site to date. A major |
355 |
part of the investment has been financed by PLIVAs own funds. |
356 |
-2 PLIVA ACQUIRES YEAST FACTORY IN SLOVAKIA</b><br> |
357 |
</a><i>Zagreb, 4th September 1998</i><i>.<br> |
358 |
PLIVA, the largest pharmaceutical company from Central and |
359 |
Eastern Europe, announces the acquisition of Fermenta, joint stock |
360 |
company in Trebiov, Slovakia ("Fermenta"). Fermenta, the |
361 |
second biggest Slovakian yeast producer, was purchased for a cash |
362 |
consideration of USD 1.3 million. |
363 |
|
364 |
-3 SECONDARY OFFERING OF PLIVA SHARES:<br> </small><small>I</small><small><small>NSTITUTIONAL PRICE FIXED AT US$ 16.60 PER GDR</small><br> STRONG INTERNATIONAL AND DOMESTIC DEMAND SHOWN</small> |
365 |
</b><i>Zagreb, 13th May 1998.</i><small><br> |
366 |
The Croatian Ministry of Finance today announced the successful |
367 |
completion of an offering of approximately 2.92 million shares |
368 |
(which includes 12.37 million GDRs) of PLIVA |
369 |
d.d. (PLIVA). |
370 |
PLIVA |
371 |
is the most profitable company in Croatia and the largest |
372 |
pharmaceutical company headquarters in Central and Eastern Europe. |
373 |
-4 PLIVA SIGNS AGREEMENT WITH WARNER-LAMBERT PHARMACEUTICAL RESEARCH TO LICENSE OUT GASTROINTESTINAL PEPTIDES |
374 |
</b><i>Zagreb, 24th April, 1998.</i><b><br> |
375 |
|
376 |
PLIVA, the largest pharmaceutical company in Central and Eastern |
377 |
Europe has signed an agreement with Parke-Davis, a division of |
378 |
Warner-Lambert Company. The agreement gives Parke-Davis an exclusive |
379 |
option to license PLIVAs newly discovered gastrointestinal |
380 |
peptides. |